BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib was first used in the treatment of chronic myelogenous leukemia (CML) to inhibit c-Abl tyrosine kinase which is constantly activated because of the fusion protein encoded by bcr-abl fusion gene due to chromosome 22 and 9 translocation [17].